Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 5 of 35
Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
NCT05634720
Accelerated TMS for Focal Hand Dystonia
NCT06015672
Creating Access to Resources and Economic Support
NCT05971160
Sling vs No Sling After Reverse Total Shoulder Arthroplasty
NCT06092996
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
NCT05634707
Eat Well Produce Benefit for Diabetes and Food Insecurity
NCT05896644
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
NCT05553834
Implementation of the ACP Guideline for Low Back Pain (IMPACt-LBP)
NCT05626049
Meaning-Centered Pain Coping Skills Training for Cancer Pain
NCT05385965
COVID-19 Quick Start - Test and Treat in Africa
NCT06360783
Xenon MRI and Progressive ILD
NCT05241275
The PASTDUe Nutrition Ecosystem Project (PASTDUe)
NCT05127109
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122
COVID-19 Vaccine Responses in PIDD Subjects
NCT05321407
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
NCT04246879
Onco-primary Care Networking to Support TEAM-based Care
NCT04258813
Well-Being After Breast Cancer Surgery
NCT04225585
Perioperative Evaluation of Cerebellar Tumors
NCT04463979
Navigation Study: Durham
NCT04438031
Peer Coaching Intervention in Young Adults With Congenital Heart Disease
NCT04271358
Improving Women's Function After Pelvic Radiation
NCT04544735
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
NCT04071769
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
NCT04207944
Duke COVID-19 Shared Data and Specimen Repository
NCT04368234
Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
NCT03694561
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
NCT03681535
Project HOPE 1000: Health Outcomes Pregnancy Exposures
NCT04417283
FCT Study: Reducing the Need for Out-of-Home Placements
NCT03641664
PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study
NCT03506451
Hepatic Resection for Metastatic Pancreatic Cancer
NCT02892305
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
NCT03403465
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
NCT02978118
Evaluation of Biomarkers in Human Synovial Fluid
NCT02664870
Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
NCT02482376
Durham Connects RCT Evaluation II
NCT01843036
Durham Connects RCT Evaluation
NCT01406184
The MURDOCK Study Registry and Biorepository Horizon 1.5
NCT01708408
University of North Carolina Alumni Heart Study
NCT00005398
Multisite Prevention of Conduct Problems (Fast Track)
NCT01653535
Vaginal Dilator Therapy After Pelvic Radiation
NCT07216456
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
NCT06999109
Mitigating Racial Disparities in Shared Decision Making in the Intensive Care Unit
NCT05710744
Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress
NCT07634419
Visual Restoration Using Focused Ultrasound Stimulation and Immersive Virtual Reality After Stroke
NCT06875206
ORASIS in Breast Reconstruction
NCT07670754
Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain Using the Education, Navigated Care, and Supported Self-management Pain Care Program
NCT07679178
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
NCT07275359
The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study
NCT07216963
SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers
NCT07429292
Compact Auto-Aligning Multi-Modal Eye Imaging to Diagnose Traumatic Eye Injury
NCT07218835
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.